Page 153 - 南京医科大学自然科学版第1期
P. 153
第41卷第1期 任筱寒,王尚乾,秦 超. 免疫检查点抑制剂在泌尿系统恶性肿瘤中的应用[J].
2021年1月 南京医科大学学报(自然科学版),2021,41(01):141-148 ·147 ·
tions for mouse and humanized models in cancer immu⁃ about⁃cancer/type/bladder⁃cancer/treatment/bladder⁃can⁃
nology and immunotherapy:a report from the associated cer ⁃stage⁃and⁃gradeadvanced
programs of the 2016 annual meeting for the Society for [18] BALAR A V,GALSKY M D,ROSENBERG J E,et al.
Immunotherapy of cancer[J]. J Immunother Cancer, Atezolizumab as first⁃line treatment in cisplatin⁃ineligible
2017,5(1):77 patients with locally advanced and metastatic urothelial
[6] INTLEKOFER A M,THOMPSON C B. At the bench:pre⁃ carcinoma:a single ⁃ arm,multicentre,phase 2 trial[J].
clinical rationale for CTLA⁃4 and PD⁃1 blockade as can⁃ Lancet,2017,389(164):67-76
cer immunotherapy[J]. J Leukoc Biol,2013,94(1):25-39 [19] BALAR A V,CASTELLANO D,O’DONNELL P H,et al.
[7] TAUBE J M,KLEIN A,BRAHMER J R,et al. Associa⁃ First⁃line pembrolizumab in cisplatin⁃ineligible patients
tion of PD⁃1,PD⁃1 ligands,and other features of the tu⁃ with locally advanced and unresectable or metastatic uro⁃
mor immune microenvironment with response to anti⁃PD⁃ thelial cancer(KEYNOTE ⁃ 052):a multicentre,single ⁃
1 therapy[J]. Clin Cancer Res,2014,20(19):5064- arm,phase 2 study[J]. Lancet Oncol,2017,18(11):
5074 1483-1492
[8] YOKOSUKA T,TAKAMATSU M,KOBAYASHI⁃IMANI⁃ [20] Study of MEDI4736(durvalumab)with or without tremeli⁃
SHI W,et al. Programmed cell death 1 forms negative co⁃ mumab versus standard of care chemotherapy in urotheli⁃
stimulatory microclusters that directly inhibit T cell recep⁃ al cancer[Z/OL].[2020⁃12⁃08]. https://clinicaltrials.gov/
tor signaling by recruiting phosphatase SHP2[J]. J Exp ct2/show/NCT02516241?term=NCT02516241&draw=
Med,2012,209(6):1201-1217 2&rank=1
[9] CARTER L L,FOUSER L A,JUSSIF J,et al. PD⁃1:PD⁃L [21] POWLES T,O’DONNELL P H,MASSARD C,et al. Effi⁃
inhibitory pathway affects both CD4(+)and CD8(+)T cacy and safety of durvalumab in locally advanced or met⁃
cells and is overcome by IL⁃2[J]. Eur J Immunol,2002, astatic urothelial carcinoma:updated results from a phase
32(3):634-643 1/2 open ⁃ label study[J]. JAMA Oncol,2017,3(9):
[10] DING H,WU X,WU J,et al. Delivering PD⁃1 inhibitory e172411
signal concomitant with blocking ICOS co ⁃ stimulation [22] PETRYLAK D P,DE WIT R,CHI K N,et al. Ramucirum⁃
suppresses lupus ⁃ like syndrome in autoimmune BXSB ab plus docetaxel versus placebo plus docetaxel in pa⁃
mice[J]. Clin Immunol,2006,118(2/3):258-267 tients with locally advanced or metastatic urothelial carci⁃
[11] BELLMUNT J,POWLES T,VOGELZANG N J. A review noma after platinum ⁃ based therapy(RANGE):a ran⁃
on the evolution of PD⁃1/PD⁃L1 immunotherapy for blad⁃ domised,double⁃blind,phase 3 trial[J]. Lancet,2017,
der cancer:the future is now[J]. Cancer Treat Rev,2017, 390(1109):2266-2277
54:58-67 [23] SHARMA P,CALLAHAN M K,BONO P,et al. Nivolum⁃
[12] ZIBELMAN M,RAMAMURTHY C,PLIMACK E R. ab monotherapy in recurrent metastatic urothelial carcino⁃
Emerging role of immunotherapy in urothelial carcinoma⁃ ma(CheckMate 032):a multicentre,open ⁃ label,two ⁃
sdvanced disease[J]. Urol Oncol,2016,34(12):538- stage,multi⁃arm,phase 1/2 trial[J]. Lancet Oncol,2016,
547 17(11):1590-1598
[13] BOEGEMANN M,AYDIN A M,BAGRODIA A,et al. [24] SHARMA P,RETZ M,SIEFKER⁃RADTKE A A,et al.
Prospects and progress of immunotherapy for bladder can⁃ Nivolumab in metastatic urothelial carcinoma after Plati⁃
cer[J]. Expert Opin Biol Ther,2017,17(11):1417-1431 num therapy(CheckMate 275):a multicentre,single⁃arm,
[14] BELLMUNT J,BAJORIN D F. Pembrolizumab for ad⁃ phase 2 trial[J]. Lancet Oncol,2017,18(3):312-322
vanced urothelial carcinoma[J]. N Engl J Med,2017,376 [25] BELLMUNT J,DE WIT R,VAUGHN D J,et al. Pembroli⁃
(23):2304 zumab as second⁃line therapy for advanced urothelial car⁃
[15] NCCN. Clinical Practice Guidelines in Oncology(NCCN cinoma[J]. N Engl J Med,2017,376(11):1015-1026
guidelines):version 5 ⁃ 2018[EB/OL].[2018 ⁃ 10 ⁃ 18]. [26] APOLO A B,INFANTE J R,BALMANOUKIAN A A,et
www.nccn.org/professionals/physician_gls/pdf/bladder.pdf al. Avelumab,an anti⁃programmed death⁃ligand 1 anti⁃
[16] ABIDA W,BAJORIN D F,ROSENBERG J E. First⁃line body,in patients with refractory metastatic urothelial car⁃
treatment and prognostic factors of metastatic bladder can⁃ cinoma:results from a multicenter,phase Ib study[J]. J
cer for platinum⁃eligible patients[J]. Hematol Oncol Clin Clin Oncol,2017,35(19):2117
North Am,2015,29(2):319 [27] 田 野,王尚乾,苗陈岿,等. 晚期肾癌免疫检查点治疗
[17] CANCER RESEARCH U K. Types,stages and grades[EB/ 新进展[J]. 南京医科大学学报(自然科学版),2019,39
OL].[2020 ⁃ 12 ⁃ 08]. http://www.cancerresearchuk.org/ (1):153-157